Catherine Mackey - GW Pharmaceuticals Non-Executive Independent Director
Director
Dr. Catherine J. Mackey is NonExecutive Independent Director of the Company. Dr. Mackey is an experienced corporate executive, director and advisor with over thirty years of accomplishment in the biotechnology, pharmaceutical, and agricultural industries. She is currently Chief Executive Officer of CYPrus Therapeutics, Inc. and Chairman of the Board of Cour Pharmaceutical Development. In addition, she serves on the Board of Directors of Rady Children Hospital and as an advisor to several companies. Dr. Mackey previously served as Senior Vice President of Pfizer Worldwide RD and Director, of Pfizer La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer main pharmaceutical research and development sites with over 1000 employees and a robust drug pipeline. Prior to that role she served as head of Strategic Alliances and also Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as Vice President of DEKALB Genetics, Inc since 2017.
Age | 60 |
Tenure | 7 years |
Professional Marks | Ph.D |
Phone | (44) 1223 235667 |
Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Darice Liu | Universal Display | N/A | |
Daniel Hirsch | Playa Hotels Resorts | 42 | |
Elizabeth Gemmill | Universal Display | 72 | |
Catherine Livingstone | Commonwealth Bank of | 61 | |
Mary Padbury | Commonwealth Bank of | 58 | |
Thomas Klein | Playa Hotels Resorts | 55 | |
Wendy Stops | Commonwealth Bank of | 56 | |
Manzo Guevara | Playa Hotels Resorts | 48 | |
Jane Hemstritch | Commonwealth Bank of | 60 | |
Richard Elias | Universal Display | 64 | |
Arturo Sarukhan | Playa Hotels Resorts | 52 | |
Gary Kelsey | Juniata Valley Financial | 54 | |
Andrew Mohl | Commonwealth Bank of | 60 | |
Sidney Rosenblatt | Universal Display | 76 | |
Paul Hackwell | Playa Hotels Resorts | 36 | |
Paul OMalley | Commonwealth Bank of | N/A | |
Genevieve Bell | Commonwealth Bank of | N/A | |
Gloria Guevara | Playa Hotels Resorts | 48 | |
Kareem Sethi | Emerson Radio | 41 | |
Kath Smith | JD Sports Fashion | 65 | |
Neil Greenhalgh | JD Sports Fashion | 52 |
Management Performance
Return On Equity | -7.92 | |||
Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director | ||
Christopher Tovey, COO, Executive Director | ||
Thomas Lynch, Non-Executive Independent Director | ||
Catherine Mackey, Non-Executive Independent Director | ||
Justin Gover, CEO, Director | ||
Geoffrey Guy, Executive Chairman of the Board | ||
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
Julian Gangolli, Executive Director | ||
Alicia Secor, Non-Executive Independent Director | ||
Adam George, CFO, Company Secretary, Director | ||
Cabot Brown, Non-Executive Independent Director | ||
Stephen Wright, Research & Development Director, Executive Director | ||
Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -7.92 | |||
Return On Asset | -3.55 | |||
Profit Margin | (11.03) % | |||
Operating Margin | (9.82) % | |||
Current Valuation | 6.42 B | |||
Shares Outstanding | 31.54 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 80.35 % | |||
Number Of Shares Shorted | 693.73 K | |||
Price To Earning | 126.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |